2026-11-14 · 2026-11 / week-2
NMAX’s 31% post-result move leaves a 5.8× sales hurdle, not a bounded long
NMAX’s 31% post-result move leaves a 5.8× sales hurdle, not a bounded long
The Mispricing Desk | 14 November 2026, 08:40 SGT | U.S. long | Reject / no-trade screen
Summary: Newsmax’s third-quarter revenue was $69.0 million, but $14.0 million came from a non-recurring advertising-contract termination fee. Excluding it, revenue still grew 21.6% and issuer-adjusted EBITDA was positive at $5.0 million. The Nov. 13 regular close was $9.58, up 31.4% after the release. At that reference, the equity is about 5.8× the midpoint of the $212–$216 million underlying revenue guide. Core growth and cash support the bull case; the available evidence does not support a 10% base return or a 5% downside bound. Reject / no trade.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Newsmax (NMAX) | Long screen | Nov. 13 close rose 31.4%; reported Q3 growth was 52.5%, underlying growth 21.6%, and the FY26 underlying guide stayed at 13% midpoint growth | Nov. 12 SEC release, presentation and 10-Q; Nov. 13 close | Next Q4/FY26 report; date unverified | One-day volume rose, but current short, holder, options and flow data are unknown | Reject; reference-only base 0%, adverse -23.9% | Close verified; live execution data absent | Core growth, positive adjusted EBITDA excluding the fee, and $137.6M cash and investments may support a premium |
| 2 | Milestone Pharmaceuticals (MIST) | Long screen | CARDAMYST revenue rose 73% sequentially to $1.0M; its Nov. 13 close was $0.52, down 20.6% after the results | Nov. 13 SEC 10-Q and issuer release; Nov. 13 close | Commercial ramp; AFib-RVR Phase 3 data expected in 2H 2028 | Current positioning unknown | Reject; long-dated clinical catalyst and capital claims defeat a bounded map | Close verified; live execution data absent | $168.9M liabilities include $60.2M convertible notes and $82.8M royalty financing; product revenue is small |
| 3 | Applied Materials (AMAT) | Long screen | FY26 revenue rose 21% to a record $34.45B; Nov. 13 close fell 2.7% | Nov. 12 issuer release; Nov. 13 close | Q1 FY27 results and semiconductor demand | Current positioning unknown | No clear price disagreement or 10/5 model | Close verified; live execution data absent | Strong results may already be reflected in a cyclical, high-expectation valuation |
| 4 | SPDR S&P 500 ETF (SPY) | Long control | Broad-market reference, not an issuer-specific gap | Nov. 13 close | No single-company catalyst | Index exposure | No specific mispricing identified | Highly liquid instrument; execution not audited | Market exposure alone does not supply an asymmetric catalyst |
Selected screen candidate: NMAX, for information value only. It is not the best executable opportunity, and it is not a buy recommendation.
Why this one now: Newsmax released Q3 results after the Nov. 12 close. NMAX then rose 31.4% in the Nov. 13 regular session. The response can be checked against the filed fee, the company’s underlying results and its unchanged full-year guide.
What should surprise the reader: Stripping the fee does not erase the operating improvement. Core revenue was a record $55.0 million, up 21.6%, and adjusted EBITDA remained positive at $5.0 million. The harder question is whether that improvement can support the valuation after the rally.
Why This Is the Best Opportunity Right Now
NMAX is the clearest fresh U.S.-long screen among the candidates because a large, dated price response meets a directly reconcilable earnings-quality question. MIST has genuine early launch progress but its pivotal AFib-RVR result is expected in 2H 2028. AMAT reported records, but this screen found no evidence that its post-result price response created a specific valuation gap. SPY is the broad-market control.
The selection is about research value, not expected trade return. NMAX fails the return and downside tests below.
Why This Can Move More Than 5% Soon
The already-observed move was greater than 5%: NMAX closed at $9.58 after a $7.29 prior close, a 31.4% rise. The Nov. 13 range was $8.45–$9.99 on 5.07 million shares, versus 1.08 million the prior session. A large event-day range and volume establish volatility and attention, not buyer identity or a short squeeze.
The next useful company test is Q4 and FY26 reporting. I did not find a confirmed report date. It should show whether underlying revenue approaches the $212–$216 million guide, whether adjusted EBITDA stays positive without the fee, and whether affiliate and licensing gains offset advertising and subscription weakness. The latest price has already moved sharply; the remaining path has no verified, dated catalyst that makes a long attractive.
10/5 Asymmetry Gate
Reject / no trade. From the $9.58 regular close used only as a reference, the six-month base case is flat, below the required +10%. The observed pre-result close of $7.29 is a credible -23.9% reversion marker, not a floor. The favorable base-to-adverse ratio is 0.0:1. Even the thesis-best sensitivity below gives only about 0.56:1 against that marker. The probability-weighted reference value is negative before costs. No evidence bounds the adverse case within 5%.
This is not a risk-free conclusion or an executable model. Current spread, depth, venue quality, volume quality and exit capacity are not verified. I do not have sufficient reliable data to quantify slippage and exit costs accurately.
The Setup
The SEC-filed Q3 release reports $69.0 million of revenue, up 52.5% year over year. It identifies $14.0 million as a non-recurring service-revenue termination payment tied to an advertising purchase agreement. Excluding the fee, revenue was $55.0 million, up 21.6%. The fee equaled about 20% of reported revenue.
Adjusted EBITDA was $19.0 million; excluding the fee, it was $5.0 million, versus a $0.9 million loss in Q3 2025. This is an issuer-defined non-GAAP measure, not free cash flow. The fee accounted for roughly 74% of reported adjusted EBITDA, so it materially lifts the headline.
The filing says the payment followed a negotiated change to the customer agreement’s remaining rights and obligations. It does not quantify the future guaranteed advertising spend surrendered. The fee may therefore be more than a one-time gain in isolation: the net value of the payment versus future business is unknown.
Underlying revenue growth was driven mainly by affiliate fees and licensing. Affiliate revenue rose 77.4% and licensing rose sharply from a small base; broadcast advertising grew 3.1%, broadcast subscriptions fell 9.4%, digital revenue fell 4.1%, and digital subscriptions fell 15.1%. That mix is more informative than the $69 million headline.
Management maintained FY26 underlying revenue guidance at $212–$216 million, about 13% midpoint growth. Including the one-time fee, its reported-revenue range is $226–$230 million. The unchanged core guide is a better run-rate reference than annualizing one quarter.
The Market Price
StockAnalysis reports a Nov. 13 regular close of $9.58 at 4:00 p.m. EST, up $2.29 or 31.41%, with a $8.45–$9.99 range and 5,065,878 shares traded. It displayed a separate $9.45 after-hours snapshot at 6:44 p.m. EST. The scenario map uses the regular close, not an after-hours mark. Neither observation is an executable quote.
The Sept. 30 filing lists 39.239 million Class A and 89.960 million Class B shares outstanding. The two classes have identical liquidation and dividend rights. At $9.58, multiplying the combined 129.200 million shares by the close gives about $1.238 billion of equity value. Dividing by the $214 million midpoint of underlying FY26 revenue guidance gives about 5.78× equity value to sales. This is not enterprise value to sales, and it is not a peer-relative valuation.
The Mispricing
The potential disagreement is between a 31.4% one-session re-rating and a 13% midpoint growth guide, while the reported quarter contains a material non-recurring fee. That is a screen, not proof that the market capitalized the fee as recurring revenue. The fee was disclosed in the release and deck; investors could see it. Core revenue still grew 21.6%, adjusted EBITDA excluding the fee was positive, and the company reports no funded debt with $137.6 million in cash and investments.
At 5.78× underlying sales, the price embeds a growth premium. Without a defensible peer set, forward margin model, current consensus estimates or a reconciled contract-value bridge, I cannot say that premium is wrong. The setup does not establish a market error.
The Positioning
Nov. 13 volume was about 4.7× Nov. 12 volume. That supports an event-driven attention inference only. The observation does not identify whether buyers were long-only funds, retail traders, dealers, shorts covering or a mix. Current short interest, securities-lending utilization, borrow terms, options positioning, holder changes and fund flows were not verified. Positioning is unknown, not crowded or squeeze-ready by inference.
The Catalyst
The Q3 release is the catalyst already observed. The next test is the Q4/FY26 report; its date was not confirmed in the sources reviewed. Track:
- FY26 underlying revenue against $212–$216 million, keeping the $14 million termination fee separate.
- Adjusted EBITDA and cash conversion without the fee.
- Affiliate renewals and licensing growth against the declines in advertising and subscriptions.
- Any issuance under the $1.2 billion standby equity purchase agreement. The 10-Q says no shares were purchased under it in the three or nine months ended Sept. 30, 2026. Capacity is not cash or issuance, but the agreement creates a potential share-supply path during its stated term.
The cheapest falsification test is the next filing: reconcile the customer contract’s termination payment with any disclosed lost or replacement advertising, then compare the fee-excluded results with the guide. Until then, a one-quarter run-rate claim is not reliable.
The Payoff
The map is a six-month sensitivity through May 14, 2027, starting at the Nov. 13 $9.58 close. It holds the Sept. 30 issued-share count at 129.200 million and uses the $214 million guide midpoint; it does not model options, warrants or possible SEPA issuance. The top case assumes a 6.5× sales multiple on the $216 million guide high; 6.5× is an explicit, uncalibrated expansion assumption, not a comparable-company estimate. The base holds the current 5.78× multiple on midpoint sales. The bottom uses the $7.29 Nov. 12 pre-result close as a partial-reversion marker. None is fair value or a price bound.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 15% | $10.87 | +13.4% | 6 months | Underlying growth exceeds the guide and the market expands the multiple to 6.5× | Low |
| Base Case | 55% | $9.58 | 0.0% | 6 months | The guide broadly holds; the current equity sales multiple does not expand | Low |
| Bottom Case | 30% | $7.29 | -23.9% | 6 months | Event enthusiasm fades toward the pre-result close as the one-time fee laps and weak ad/subscription lines persist | Low |
| Invalidation | n/a | Insufficient data | Not a price stop | 6 months | A disclosed contract bridge and sustained fee-excluded growth would require a new valuation, not an automatic entry | Low |
Probabilities are subjective scenario weights, not observed frequencies. No close historical comparator set was verified. The weighted reference value is $9.09, or -5.2% gross from $9.58 before costs. A +10% base target would be $10.54 and would require roughly 6.36× midpoint sales. The base case is flat, adverse risk is 23.9%, and base reward/adverse risk is 0.0:1. The model fails 10/5.
Current market level and timestamp: $9.58, Nov. 13, 2026, 4:00 p.m. EST; regular close, reference only.
Primary instrument: NMAX Class B common stock, USD. No entry is set.
10/5 favorable base move: 0.0%.
10/5 credible adverse move: 23.9% to the pre-result close marker; downside beyond it is possible.
10/5 measurement basis: reference-only, not a verified entry.
10/5 status: Reject.
Confidence: Low. The earnings-quality bridge is primary-source verified; market expectations, contract economics, positioning and valuation comparables are not.
The Kill Shot
The strongest bull case is real: underlying Q3 revenue was a record, up 21.6%; adjusted EBITDA excluding the fee was positive; affiliate and licensing revenue expanded; and the company reported no funded debt alongside $137.6 million of cash and investments. The stock may deserve a premium if those trends persist.
The fragile assumption behind a fade is that the $14 million fee explains too much of the rally. The company disclosed the fee and the underlying growth in the same release. If fee-excluded growth holds near or above 20%, the current valuation may prove supportable. That defeats a simplistic “one-time fee means sell” thesis, but it still does not give a long a +10% base or cap downside.
What Could Go Wrong
The next report may confirm durable affiliate and licensing growth, and political engagement could support later cycles. The company has liquidity and no funded debt, reducing near-term funding risk. Against that, broadcasting subscriptions and digital subscriptions fell, ad growth was modest, the terminated contract’s lost future economics are undisclosed, and the SEPA could add shares if used. A sharp move, halt, after-hours gap or thin opening book could make realized returns materially worse than this close-based map.
What Would Prove This Wrong
Reopen the screen if the next filing shows the $212–$216 million underlying guide is met or raised, fee-excluded adjusted EBITDA remains positive and expands, and the contract amendment does not remove material future customer spend. Rebuild the per-share valuation with current issued and potential shares. A fresh regular-session quote, spread, depth, volume quality and exit-liquidity check would still be required before any trade could qualify.
Risk Audit
- Strongest counterargument: the underlying business improved materially, and the one-time adjustment still leaves positive adjusted EBITDA.
- Load-bearing uncertainty: the contract’s termination fee may replace future guaranteed advertising; the filing does not quantify the net effect.
- Why a directionally right view can lose: affiliate and licensing renewals, audience engagement or market sentiment may expand the multiple faster than reported growth slows.
- Market and execution risk: current short/holder data, live spread, depth, venue quality, volume quality and exit capacity are unavailable. Gap, halt, litigation, political-ad, distribution, dilution and weekend-news risk remain.
- Thesis invalidation: sustained fee-excluded growth and margin improvement at or above the guide require a fresh valuation.
- Execution cancellation: if the regular-session quote, order book or exit capacity is unverified, keep entry null and trading disabled.
Best Trade Strategy
No trade. The research record uses NMAX common stock only as the screened instrument. entry.price remains null; execution.can_execute is false. Do not use options, leverage, margin, market orders or a price-floor rule. Revisit after the next filing and a fresh regular-session market-structure check. This signal is research context, not a pending order.
Sources
- Newsmax, Q3 2026 earnings release, SEC Exhibit 99.1, Nov. 12, 2026.
- Newsmax, Nov. 2026 investor presentation, SEC exhibit, Nov. 12, 2026.
- Newsmax, Q3 2026 Form 10-Q, filed Nov. 12, 2026.
- NMAX regular close, after-hours snapshot and history, StockAnalysis, Nov. 13, 2026.
- Milestone Pharmaceuticals, Q3 2026 results and cost-efficiency release, Nov. 13, 2026.
- Milestone Pharmaceuticals, Q3 2026 Form 10-Q, filed Nov. 13, 2026.
- MIST regular close and history, StockAnalysis, Nov. 13, 2026.
- Applied Materials, Q4 and FY2026 results, Nov. 12, 2026.
- AMAT regular close and history, StockAnalysis, Nov. 13, 2026.
- SPY regular close and history, StockAnalysis, Nov. 13, 2026.
Research Quality Scorecard
| Criterion | Score | Evidence-based reason |
|---|---|---|
| Market disagreement | 4/5 | Large post-result move, non-recurring revenue and retained core growth are directly reconciled; consensus expectations are unavailable |
| Evidence base | 4/5 | Current SEC results, 10-Q and presentation; contract economics remain undisclosed |
| Positioning and flows | 2/5 | Volume is observed, but current holders, short interest and derivatives are unknown |
| Catalyst path | 3/5 | Next results can test the guide; the date and contract reconciliation are not yet known |
| Payoff architecture | 2/5 | Transparent reference sensitivity, but no independent multiple anchor or bounded downside |
| Invalidation discipline | 4/5 | Next filing and regular-session execution gates are explicit |
| Differentiated insight | 4/5 | The fee is material, but so is the fee-excluded growth and positive adjusted EBITDA; the contract may have surrendered future spend |
| Client value | 4/5 | Shows why the one-time-fee bear case alone is incomplete and why a long still fails 10/5 |
| Total | 27/40 | Reject / no-trade; failed economics take precedence over a Watchlist score |
Bottom Line
NMAX is not just a $14 million one-time-fee story: fee-excluded growth and adjusted EBITDA improved. But a 31.4% post-result rise leaves a 5.78× equity-sales reference against a 13% underlying guide, with no verified catalyst or downside bound that clears 10/5. The long screen is Reject / no trade. The signal remains watch only as non-executable research context.
AI Illustration Prompt
Create a restrained financial-editorial illustration: a television studio rundown sheet beside two stacked revenue ledgers, one clearly marked “$14M termination fee” and the other “$55M underlying revenue,” while a price line jumps upward and then meets a broad, unmarked valuation band. Avoid real logos, political figures, flags, or partisan colors. Use calm navy, paper white, and muted amber; place a small, readable “The Mispricing Desk” watermark in the lower-right corner.